Tempus AI Gains After New Bristol Myers Deal and EU Diagnostic Certification

Tempus AI, Inc. (TEM) is up 7.7% today. Here is some analysis on what might have caused this price movement.

Analysis: The rally appears tied to a combination of fresh commercial and regulatory news. Investors likely reacted to Tempus disclosing a large multi-year data and software agreement tied to Bristol Myers Squibb and Pathos, while also welcoming a new European certification for its xR solid tumor profiling assay.

Details:

Tempus filed an 8-K on October 23, 2026 describing agreements with Bristol Myers Squibb and Pathos that provide for aggregate cash payments to Tempus of $192.5 million over roughly five years.

The oncology portion of the arrangement gives Bristol Myers Squibb access to Tempus’ multimodal oncology data, Lens software, and related analysis services through 2031, which strengthens the company’s data and applications revenue story.

Tempus also announced on October 26, 2026 that its xR assay received European Union IVDR Class C certification, a regulatory milestone that can support broader adoption of the test in cancer genomic profiling.

With third-quarter 2026 results scheduled for November 2, 2026, this string of positive updates may have added momentum as traders position for another checkpoint on growth and execution.

Sources:

SEC, Tempus AI, Yahoo Finance

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$TEM Insider Trading Activity

$TEM insiders have traded $TEM stock on the open market 124 times in the past 6 months. Of those trades, 0 have been purchases and 124 have been sales.

Here’s a breakdown of recent trading of $TEM stock by insiders over the last 6 months:

ERIC P LEFKOFSKY (CEO and Chairman) has made 0 purchases and 86 sales selling 1,603,676 shares for an estimated $96,492,282.
RYAN FUKUSHIMA (CEO, Data) has made 0 purchases and 14 sales selling 142,447 shares for an estimated $7,295,870.
JAMES WILLIAM ROGERS (Chief Financial Officer) has made 0 purchases and 4 sales selling 71,224 shares for an estimated $3,808,830.
ANDREW POLOVIN (EVP, Chief Legal Officer) has made 0 purchases and 4 sales selling 41,729 shares for an estimated $2,147,540.
THOMAS EDWARD SCHOENHERR (CEO, Diagnostics) has made 0 purchases and 9 sales selling 29,175 shares for an estimated $1,873,506.
RYAN M BARTOLUCCI (Chief Accounting Officer) has made 0 purchases and 3 sales selling 17,353 shares for an estimated $1,017,383.
NADJA WEST sold 3,000 shares for an estimated $207,000
JENNIFER A DOUDNA sold 2,673 shares for an estimated $147,015
DAVID R EPSTEIN has made 0 purchases and 2 sales selling 620 shares for an estimated $28,408.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

$TEM Hedge Fund Activity

We have seen 277 institutional investors add shares of $TEM stock to their portfolio, and 199 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

JPMORGAN CHASE & CO added 4,989,062 shares (+inf%) to their portfolio in Q2 2026, for an estimated $289,016,361
GC WEALTH MANAGEMENT RIA, LLC removed 4,199,843 shares (-63.5%) from their portfolio in Q2 2026, for an estimated $243,296,904
GOLDMAN SACHS GROUP INC added 2,483,910 shares (+194.4%) to their portfolio in Q2 2026, for an estimated $143,892,906
MORGAN STANLEY added 1,568,701 shares (+75.3%) to their portfolio in Q2 2026, for an estimated $90,874,848
BANK OF AMERICA CORP /DE/ added 1,502,992 shares (+362.4%) to their portfolio in Q2 2026, for an estimated $87,068,326
D. E. SHAW & CO., INC. removed 1,180,315 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $68,375,647
SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 852,916 shares (+inf%) to their portfolio in Q2 2026, for an estimated $49,409,423

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$TEM Government Contracts

We have seen $30,754,366 of award payments to $TEM over the last year.

Here are some of the awards which we have have seen pay out the most over the last year:

ADAPT CRO SUPPORT SERVICES SOLICITATION: $11,637,449

To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard. You can access data on government contracts through the Quiver Quantitative API government contracts endpoint.

$TEM Price Targets

Multiple analysts have issued price targets for $TEM recently. We have seen 5 analysts offer price targets for $TEM in the last 6 months, with a median target of $68.0.

Here are some recent targets:

Gene Mannheimer from Freedom Capital Markets set a target price of $59.0 on 07/01/2026
Ryan MacDonald from Needham set a target price of $75.0 on 06/01/2026
Mark Massaro from BTIG set a target price of $80.0 on 06/01/2026
Yi Chen from HC Wainwright & Co. set a target price of $64.0 on 05/11/2026
Dan Brennan from TD Cowen set a target price of $68.0 on 05/06/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.